Eledon shareholders approve increase in authorized common shares to 300M

Eledon Pharmaceuticals, Inc.

Shareholders approved increase in authorized common stock from 200M to 300M shares (40.79M for, 0.49M against).
Approved amendment to extend officer exculpation protection to fullest extent under Delaware law (30.04M for, 1.29M against).
Elected Class II directors Keith Katkin, Allan Kirk, and John McBride for three-year terms ending 2028.
Ratified Deloitte & Touche as independent auditor for FY2025 (41.31M for, 36k against).
Authorized share increase and officer exculpation amendments became effective June 10, 2025.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Eledon Pharmaceuticals, Inc.: Extended exculpation protection to officers to the fullest extent permitted by Delaware law.

Change: charter amendment

Exact text from the filing

a Certificate of Amendment (the “Officer Exculpation Amendment”) to amend the Certificate of Incorporation to extend exculpation protection to officers, to the fullest extent permitted by Delaware law

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Eledon Pharmaceuticals, Inc.: Increased authorized shares of common stock from 200,000,000 to 300,000,000.

Change: charter amendment

Exact text from the filing

the Company filed the following with the Secretary of State of the State of Delaware: • a Certificate of Amendment (the “Authorized Share Increase Amendment”) to the Company’s Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) to amend the Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000 shares

View on SEC.gov

Browse all governance changes →

Eledon Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-085588

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.